BLACK DIAMOND THERAPEUTICS INC (BDTX)
Health Care · Clinical-stage targeted oncology / kinase inhibitors · NASDAQ
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey inhibitors designed to target families of oncogenic mutations across multiple cancer types, with a focus on brain-penetrant therapies for lung cancer and glioblastoma.
What BLACK DIAMOND THERAPEUTICS INC does
Black Diamond Therapeutics is a clinical-stage oncology company focused on developing targeted therapies for genetically defined cancers. The company's proprietary MasterKey approach enables single molecules to address families of oncogenic mutations by exploiting their shared activating conformations. Its lead program, silevertinib, is a brain-penetrant, fourth-generation EGFR inhibitor currently in Phase 2 trials for EGFR-mutant non-small cell lung cancer, with plans to expand into EGFR-altered glioblastoma.
Themes: oncology / targeted cancer therapy, EGFR inhibitors, brain-penetrant / CNS oncology, non-small cell lung cancer (NSCLC), glioblastoma, acquired resistance mutation targeting, precision oncology / genetic mutations
Fundamentals
- Price$2.21 as of 2026-08-21 close
- Market cap$127M as of 2026-08-21
- 1-year return-18.5% 2025-08-21 close $2.71 → 2026-08-21 close $2.21
- P/E5.23 as of 2026-08-24
- Net margin+31.9% as of 2026-08-24
- ROE-36.4% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta3.27 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How BDTX compares in its sector
- price-to-earnings ratiobottom 10% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How BLACK DIAMOND THERAPEUTICS INC looks technically
BLACK DIAMOND THERAPEUTICS INC (BDTX) is trading 13.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 135 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-06-01, pushing above its recent trading range. It is 55.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 13.0% below its 200-day average, the long-term trend line — a long-term downtrend | -13.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.86 | $1.86 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.54 | $2.54 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 1.62. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 135 trading days ago — a "death cross", a bearish long-term signal | 135 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control | 26.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30) | 66.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($1.74 to $2.26) — its "stochastic" reading is 90 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 90.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.94 | $4.94 |
|---|---|---|
| From the 52-week high | it is 55.3% below its 52-week high (its highest price of the past year) | -55.3% |
| Above the 52-week low | it is 38.1% above its 52-week low (its lowest price of the past year) | +38.1% |
| Below the 52-week high | it is 55.3% below its highest point of the past year | 55.3% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-06-01, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 44 trading days ago | 44 sessions |
| All-time high | its highest closing price on record is $46.25 (set on 2020-06-03) | $46.25 |
| Given back of the 52-week move | over the past year its closes ranged ($1.61 to $4.87), and it has recovered roughly a quarter of its fall from last year’s high — 18% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.62 to $3.73. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 18.4% |
| From the all-time high | it is 95.2% below its all-time high | -95.2% |
| Nearest price level | it is trading 0.5% below a resistance level at $2.22 — a price it turned at four times since 2025-05-20, most recently on 2026-07-07. Since 2024-08-21 it has 3 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.5% |
| All-time low | its lowest closing price on record is $1.18 (set on 2022-10-17) | $1.18 |
| Above the all-time low | it is 87.3% above its all-time low | +87.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 68th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1097 between its high and its low — about 5.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1097 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.58 and $2.28 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.58 – $1.93 – $2.28 |
| Typical daily range (% of price) | its price moves about 5.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.0% |
| Stretch from the 200-day average | it is trading 3.0 daily ranges below its 200-day average price (13.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.97× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.4% since the prior reading | +1.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 15.2% below the previous close 59 sessions ago and has not traded back through the level it left behind at 3.55 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -15.2% |
| Gap filled | a 3.8% gap up opened on 2026-08-04 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 13 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 15.9 percentage points (the stock gained 18.2% while the market gained 2.3%) | +15.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 40.8 percentage points (the stock lost 37.7% while the market gained 3.1%) | -40.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 16.2 percentage points (the stock lost 5.2% while the market gained 11.1%) | -16.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 38.9 percentage points (the stock lost 18.5% while the market gained 20.5%) | -38.9% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 37.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.33 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -5.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $2.06 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +7.3% |
Price levels it has turned at before
BDTX last closed at $2.21 on 2026-08-21. Since 2024-08-21 it has turned at 3 prices below its last close and 11 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.22 | Resistance | 0.5% above the last close | turned there four times · 2025-05-20 to 2026-07-07 |
| $2.13 | Support | 3.4% below the last close | turned there three times · 2025-02-12 to 2026-02-12 |
| $2.31 | Resistance | 4.6% above the last close | turned there three times · 2024-11-21 to 2026-03-17 |
| $2.35 | Resistance | 6.6% above the last close | turned there twice · 2024-12-27 to 2026-01-20 |
| $1.91 | Support | 13.5% below the last close | turned there three times · 2025-01-10 to 2026-07-22 |
| $1.59 | Support | 27.8% below the last close | turned there twice · 2025-03-10 to 2026-06-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $1.62.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.44 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$10.00 range $8.00 – $14.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BDTX
- Consensus EPS estimate-$0.055 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage development risk: silevertinib is in Phase 2 trials with uncertain outcomes; failure to meet efficacy or safety endpoints could delay or halt development and revenue generation","Competitive landscape: the EGFR inhibitor space is crowded with established players (osimertinib, afatinib) and other development-stage competitors; loss of Fast Track status or clinical trial setbacks could impair market position","Revenue dependency: the company received $70 million in license revenue in Q1 2025 but had zero license revenue in Q1 2026, indicating reliance on potentially non-recurring partnerships or milestone payments"]
What changed in the latest 10-Q
AI-assisted comparison of BDTX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Silevertinib described as 'covalent, fourth-generation' EGFR inhibitor (newer filing)
- Initiated a randomized Phase 2 trial of silevertinib in newly diagnosed EGFRvIII+ glioblastoma with first patient dosed in May 2026 (newer filing)
- Initial data from Phase 2 trial of 83 patients with EGFRm NSCLC in second- and third-line settings announced (newer filing)
- December 2025 announcement of initial data from 43 frontline NSCLC patients with specific efficacy metrics: 60% ORR, 86% CNS ORR, 91% DCR (newer filing)
- Efficacy and safety data assessed with November 3, 2025 data cutoff with 7.2 months median follow-up (newer filing)
- 29 patients remained on therapy as of November 3, 2025 data cutoff, with one patient on therapy for more than 19 months (newer filing)
- Plan to present updated results at ASCO Annual Meeting May 29–June 2, 2026 (newer filing)
- Silevertinib achieved 86% CNS response rate in Phase 2 frontline NSCLC patients (newer filing)
- FDA feedback on study design received in January 2026 for GBM trial (newer filing)
- Randomized Phase 2 GBM trial design details: approximately 150 newly diagnosed EGFRvIII-positive, MGMT-negative patients; TMZ control vs. silevertinib plus TMZ; primary endpoint PFS by RANO via BICR; interim analysis anticipated first half 2028; secondary endpoint OS; IDMC governance (newer filing)
- BDTX-4933 outlicensed to Servier in first quarter of 2025 (newer filing)
- Removed:
- Reference to audited consolidated financial statements for year ended December 31, 2024 and 10-K filed March 6, 2025 (older filing references removed in newer)
- Description of silevertinib as 'fourth-generation' without 'covalent' modifier in overview (older filing)
- Statement about March 2025 global licensing agreement announcement and $70.0 million upfront payment in overview section (older filing, moved/reorganized in newer)
- Description of BDTX-4933 as 'potential best-in-class targeted therapy for RAF/RAS-mutant solid tumors' in overview (older filing)
- Statement 'We are currently evaluating silevertinib in a Phase 2 clinical trial' language (older filing)
- Planned announcement of initial results from cohort 3 in fourth quarter of 2025 (older filing)
- Plan to solicit FDA feedback in first half of 2026 (older filing)
- Detailed September 2024 Phase 2 data announcement with 27 patients, 42% ORR in osimertinib-resistant mutations, PACC mutation discussion (older filing)
- Reference to June 2024 ASCO presentation of Phase 1 GBM data (older filing)
- Detailed Ivy Brain Tumor Center trial presentation history (EANO October 2024, SNO November 2024, AACR April 2025, EANO October 2025) (older filing)
- Statement about March 2025 modification of Phase 0/1 trial to include newly diagnosed GBM patients (older filing)
- Detailed Servier Agreement terms in body text with $70.0 million upfront and up to $710.0 million milestone payments (older filing)
- Reworded:
- Overview section reorganized: BDTX-4933 Servier agreement moved from early overview paragraph to later in text in newer filing
- Older filing states 'We are currently evaluating silevertinib in a Phase 2 clinical trial in patients with EGFRm NSCLC in both the recurrent setting (cohorts 1 and 2) and the frontline setting (cohort 3)' replaced with newer filing language describing completed enrollment and announced data with specific trial metrics
- Older filing: 'Enrollment in frontline patients...was completed in July 2025, and we are on track to announce initial results from this cohort in the fourth quarter of 2025' versus newer filing: 'In July of 2025, we completed enrollment of 43 patients...In December of 2025, we announced initial data'
- Clinical trial descriptions shift from forward-looking/anticipated language (older) to completed/announced results language (newer)
- GBM trial strategy: older filing discusses modified Phase 0/1 trial, newer filing describes newly initiated randomized Phase 2 trial as primary development path
- Notes:
- Older filing appears to be Q3 2025 10-Q (ended September 30, 2025); newer filing is Q1 2026 10-Q (ended March 31, 2026), spanning approximately six months of company developments and data announcements
- Much of the 'removal' content in older filing reflects forward-looking statements that became historical facts in newer filing rather than substantive deletion
- Some content reorganization between filings may reflect different presentation structure rather than material changes
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for BDTX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding BDTX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,192,479
- Reported value $8,929,981
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BDTX had 5,862,939 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BDTX had 10.2% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.7 days to cover at the same settlement.
- Reported short interest (shares) 5,862,939
- Short interest (% of shares outstanding) 10.2%
- Prior settlement (shares) 5,851,617
- Reported change 0.19%
- Days to cover (reported) 8.7
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AstraZeneca (AZN)
- Novartis (NVS)
- Eli Lilly (LLY)
- Blueprint Medicines (BPMC)
- Revolution Medicines (RVMD)
- Mirati Therapeutics (acquired by BMY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BDTX vs…
Frequently asked questions
What does BLACK DIAMOND THERAPEUTICS INC (BDTX) do?
Black Diamond Therapeutics is a clinical-stage oncology company focused on developing targeted therapies for genetically defined cancers. The company's proprietary MasterKey approach enables single molecules to address families of oncogenic mutations by exploiting their shared activating conformations.
What sector is BLACK DIAMOND THERAPEUTICS INC (BDTX) in?
BLACK DIAMOND THERAPEUTICS INC (BDTX) is classified in the Health Care sector. Its industry is Clinical-stage targeted oncology / kinase inhibitors. It trades on NASDAQ.
Who are BLACK DIAMOND THERAPEUTICS INC's (BDTX) competitors?
Notable peers of BLACK DIAMOND THERAPEUTICS INC (BDTX) include AstraZeneca, Novartis, Eli Lilly, Blueprint Medicines and Revolution Medicines. This peer set is informational only — not financial advice.
Is BLACK DIAMOND THERAPEUTICS INC (BDTX) overbought or oversold right now?
BLACK DIAMOND THERAPEUTICS INC (BDTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 67, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BDTX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.